Compare · DFTX vs IMCC
DFTX vs IMCC
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and IM Cannabis Corp. (IMCC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and IMCC operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $4.60B, about 2100.9x IMCC ($2.2M).
- IMCC has been more active in the news (14 items in the past 4 weeks vs 11 for DFTX).
- DFTX has more recent analyst coverage (8 ratings vs 3 for IMCC).
- Company
- Definium Therapeutics Inc.
- IM Cannabis Corp.
- Price
- -
- -
- Market cap
- $4.60B
- $2.2M
- 1M return
- -
- -21.84%
- 1Y return
- -
- -97.58%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 11
- 14
- Recent ratings
- 8
- 3
IMCC
IM Cannabis Corp.
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel, Germany, and Canada. It offers strains under the Roma, Dairy Queen, London, Tel Aviv, Paris, and Pandora Box brands; and CBD oil products under the IMC brand. The company also offers its intellectual property related services to the medical cannabis industry. IM Cannabis Corp. is headquartered in Tel Aviv-Yafo, Israel.
Latest DFTX
- Definium Therapeutics Announces New Employee Inducement Grants
- Analyst initiated coverage on Definium Therapeutics with a new price target
- Chief Medical Officer Karlin Daniel sold $396,894 worth of shares (10,853 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 792,846 units (SEC Form 4) (withholding obligation)
- Chief Executive Officer Barrow Robert sold $1,153,784 worth of shares (31,550 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 2,213,090 units (SEC Form 4) (for withholding tax)
- Chief Commercial Officer Wiley Matthew T. sold $113,257 worth of shares (3,097 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.86% to 359,036 units (SEC Form 4) (for tax liability)
- Chief Legal Officer Sullivan Mark sold $513,845 worth of shares (14,051 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 494,228 units (SEC Form 4) to satisfy withholding tax
- Chief Financial Officer Roberts Brandi sold $123,497 worth of shares (3,377 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.85% to 394,528 units (SEC Form 4) (withholding tax)
- Definium Therapeutics Announces New Employee Inducement Grants
- SEC Form 144 filed by Definium Therapeutics Inc.
- SEC Form 144 filed by Definium Therapeutics Inc.
Latest IMCC
- SEC Form F-3 filed by IM Cannabis Corp.
- SEC Form 6-K filed by IM Cannabis Corp.
- SEC Form SCHEDULE 13G filed by IM Cannabis Corp.
- IM Cannabis Announces Closing of the Sale of IMC Holdings and Its European-Focused Operations, Strengthens Balance Sheet
- SEC Form 6-K filed by IM Cannabis Corp.
- SEC Form 6-K filed by IM Cannabis Corp.
- IM Cannabis Announces Closing of US$1.31 Million Registered Direct Offering of Common Shares
- SEC Form 424B5 filed by IM Cannabis Corp.
- SEC Form 6-K filed by IM Cannabis Corp.
- SEC Form 6-K filed by IM Cannabis Corp.